Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why AbbVie Just Made a $1.8 Billion Gene Therapy Deal

By Keith Speights and Brian Orelli, PhD - Sep 25, 2021 at 6:55AM

Key Points

  • AbbVie is partnering with Regenxbio to develop a gene therapy targeting eye diseases.
  • Regenxbio's gene therapy is already in late-stage testing.
  • The deal could give AbbVie a near-term growth driver and generate needed cash for Regenxbio.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The big drugmaker wants another near-term growth driver.

AbbVie ( ABBV 0.07% ) recently announced a collaboration with Regenxbio ( RGNX 3.10% ) to develop a gene therapy targeting wet age-related macular degeneration. The deal could be worth up to nearly $1.8 billion including milestone payments. In this Motley Fool Live video recorded on Sept. 15, Motley Fool contributors Keith Speights and Brian Orelli discuss why AbbVie is teaming up with Regenxbio.

Keith Speights: All right. Let's switch from COVID-19 to a non-COVID story now. AbbVie, the ticker for AbbVie as ABBV. AbbVie recently announced a partnership with Regenxbio, that ticker for Regenxbio is RGNX.

The two companies are developing a gene therapy together targeting wet age-related macular degeneration or AMD. This deal could be worth up to nearly $1.8 billion and that includes milestone payments.

Brian, why did AbbVie team up with Regenxbio? Do you think this is a smart move for the company?

Brian Orelli: AbbVie really needs near-term growth. I mean, this gene therapy which goes by RGNX 314 is in late-stage testing. They are already in one pivotal study already. Then they're going to run us than pivotal means that that's the study that we're going to send to the FDA for approval.

Then the second pivotal trial is on track to start in the fourth quarter. They'll have data within, I guess, probably a little over a year from now. Then approval 8-12 months after that. That should help AbbVie in the near term to try to increase its revenue. Because of course, it's losing Humira to biosimilar competition.

It seems like it's a pretty good deal for Regenxbio, and the shares popped on the news of the deal. Investors definitely thought it was, it only has to give up half of the value inside the US, the companies will share the profits equally in the US. Then outside the US, it's going to get a royalty. Probably didn't really want to expand outside the US.

Anyways, there is initially I know that it's a fairly small company. I think you can probably do a deal outside the US anyway. I don't think we got what exactly the royalties are going to be. But presumably, hopefully, they get a good royalty deal to justify giving away the full rights outside the US.

Then Regenxbio also gets $374 million upfront and which will help pay for their clinical trials. Then there's potential for 1.3 billion in additional development, regulatory and commercial milestones. Presumably, a lot of that in the commercial milestone bucket, but they don't break it out.

But you can pretty much assume that a lot of it will be bonuses based on the actual sales rather than development or approval milestones. But they'll probably get some money for completing the Phase III you're completing earlier stages testing the gene therapy and other eye diseases, and then of course, approvals, it'll get some bonuses as well.

Speights: I think we'll just have to wait and see if this ends up being a really smart move for AbbVie. Obviously, if this gene therapy pans out, it's going to look like a brilliant move in hindsight.

Orelli: But $70 million is they're risking something, but they've seen in the Phase II data so they know what they're getting themselves into. I think it's a fairly good risk, but I think it's a better deal for Regenxbio and it's probably has something to do with AbbVie's need for near-term catalysts and the lack of Phase III products on the market by small companies that they want to find a partner.



This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AbbVie Inc. Stock Quote
AbbVie Inc.
ABBV
$121.59 (0.07%) $0.08
REGENXBIO Inc. Stock Quote
REGENXBIO Inc.
RGNX
$32.95 (3.10%) $0.99

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
652%
 
S&P 500 Returns
142%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/08/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.